MR. KEMAR ORLANDO BARRETT MD
Prescription History 1144896606
Internal Medicine - Infectious Disease in Rochester, MN
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MR. KEMAR ORLANDO BARRETT MD, an active Infectious Disease specialist practicing in Rochester, MN. Our medical registry currently tracks 1 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 17 documented patient claims. Among these therapy options, the most frequently utilized medication is Biktarvy, which accounts for 17 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2024)Rx (2024) | Avg Cost per FillCost / Fill | Vs. Other MN PrescribersVs. MN Avg |
|---|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 17 | $3,926.10▼ below MN avg | ▼ Less than typical |
About Biktarvy: This combination product is used by itself to help control HIV infection. Show more ▾ It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details. In 2024, this provider wrote 17 Medicare prescriptions for Biktarvy, about a quarter of the volume of the typical Minnesota prescriber of this medication (67.8). Medicare paid an average of $3,926.10 per fill, versus $4,052.82 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average MN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MN average for this medication. 17 30-Day Fills standardized to 30-day supplies 510 Days of Medication total across all patients in 2024 | |||
About this data. The prescription history for MR. KEMAR ORLANDO BARRETT MD is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2024, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Infectious Disease prescribing approach at this Rochester, MN practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average among MN prescribers of the same medication and form, shown only when at least five prescribers contribute. Always confirm current medications and costs directly with the provider and your plan.
About the medication summaries. Drug use descriptions come from the CMS Medicare Part D Drug Spending Dashboard (2024), and substance definitions from Medical Subject Headings (MeSH) 2026, U.S. National Library of Medicine. They are summaries that do not contain all possible information about a medication and are not individual medical advice. Ask a health care professional about any medication and your specific health needs.
